2 active not recruiting, 2 completed, 1 terminated, 1 unknown. 6 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
Follow INCAGN01876: new trials by email Literature Review of INCAGN01876 trials Research Report on INCAGN01876
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma INCAGN01876, retifanlimab - Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies | Phase 2 | Withdrawn | Incyte Biosciences International Sàrl | 2023-03-01 | 2023-09-15 | |
| Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC INCAGN01876, INCMGA00012, DPV-001 - Cancer of the Head and Neck | Phase 1 | Active not recruiting | Providence Health & Services | 19 | 2021-08-05 | 2026-09-03 |
| Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma INCMGA00012, INCAGN01876, SRS - Glioblastoma | Phase 2 | Active not recruiting | University of Pennsylvania | 39 | 2020-06-23 | 2026-06-23 |
| INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies INCAGN01876, Epacadostat, Pembrolizumab - Advanced Malignancies, Metastatic Cancer | Phase 1 / Phase 2 | Terminated | Incyte Biosciences International Sàrl | 10 | 2017-11-21 | 2021-07-22 |
| Biomarker-based Study in R/M SCCHN Afatinib, Palbociclib, standard of care - Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Unknown | European Organisation for Research and Treatment of Cancer - EORTC | 340 | 2017-11-16 | 2023-11-03 |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies INCAGN01876, Nivolumab, Ipilimumab - Advanced Malignancies, Metastatic Cancer | Phase 1 / Phase 2 | Completed | Incyte Biosciences International Sàrl | 145 | 2017-04-25 | 2025-08-14 |
| A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors INCAGN01876 - Advanced Malignancies, Metastatic Cancer | Phase 1 / Phase 2 | Completed | Incyte Biosciences International Sàrl | 100 | 2016-06-20 | 2021-02-26 |
Squamous Cell Carcinoma of Head and Neck (4) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (3) · Melanoma (3) · Neoplasm Metastasis (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Merkel Cell (2) · Carcinoma, Transitional Cell (2) · Endometrial Neoplasms (2) · Mesothelioma (2) · Ovarian Neoplasms (2) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Uterine Cervical Neoplasms (2)
Incyte Biosciences International Sàrl (4) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Providence Health & Services (1) · University of Pennsylvania (1)
United States (6) · Belgium (2) · Spain (2) · Australia (1) · France (1) · Italy (1) · United Kingdom (1)
John E. Janik, MD (1) · John Janik, MD (1) · John N. Janik, MD (1) · Nawel Bourayou, MD (1) · Stephen Bagley, MD, MSCE (1)
2016 (1), 2017 (1)